Literature DB >> 23945077

Receptor-directed chimeric toxins created by sortase-mediated protein fusion.

Andrew J McCluskey1, R John Collier.   

Abstract

Chimeric protein toxins that act selectively on cells expressing a designated receptor may serve as investigational probes and/or antitumor agents. Here, we report use of the enzyme sortase A (SrtA) to create four chimeric toxins designed to selectively kill cells bearing the tumor marker HER2. We first expressed and purified: (i) a receptor recognition-deficient form of diphtheria toxin that lacks its receptor-binding domain and (ii) a mutated, receptor-binding-deficient form of anthrax-protective antigen. Both proteins carried at the C terminus the sortase recognition sequence LPETGG and a H₆ affinity tag. Each toxin protein was mixed with SrtA plus either of two HER2-recognition proteins--a single-chain antibody fragment or an Affibody--both carrying an N-terminal G₅ tag. With wild-type SrtA, the fusion reaction between the toxin and receptor-recognition proteins approached completion only after several hours, whereas with an evolved form of the enzyme, SrtA*, the reaction was virtually complete within 5 minutes. The four fusion toxins were purified and shown to kill HER2-positive cells in culture with high specificity. Sortase-mediated ligation of binary combinations of diverse natively folded proteins offers a facile way to produce large sets of chimeric proteins for research and medicine. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23945077      PMCID: PMC3795991          DOI: 10.1158/1535-7163.MCT-13-0358

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  55 in total

1.  Stoichiometry of anthrax toxin complexes.

Authors:  Jeremy Mogridge; Kristina Cunningham; R John Collier
Journal:  Biochemistry       Date:  2002-01-22       Impact factor: 3.162

2.  Structure of sortase, the transpeptidase that anchors proteins to the cell wall of Staphylococcus aureus.

Authors:  U Ilangovan; H Ton-That; J Iwahara; O Schneewind; R T Clubb
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-22       Impact factor: 11.205

3.  The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen.

Authors:  Jeremy Mogridge; Kristina Cunningham; D Borden Lacy; Michael Mourez; R John Collier
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

4.  Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen.

Authors:  Kristina Cunningham; D Borden Lacy; Jeremy Mogridge; R John Collier
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

5.  Purification and characterization of sortase, the transpeptidase that cleaves surface proteins of Staphylococcus aureus at the LPXTG motif.

Authors:  H Ton-That; G Liu; S K Mazmanian; K F Faull; O Schneewind
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

6.  Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor.

Authors:  Heather M Scobie; G Jonah A Rainey; Kenneth A Bradley; John A T Young
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-16       Impact factor: 11.205

7.  Identification of the cellular receptor for anthrax toxin.

Authors:  K A Bradley; J Mogridge; M Mourez; R J Collier; J A Young
Journal:  Nature       Date:  2001-11-08       Impact factor: 49.962

8.  Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody.

Authors:  M J Rosovitz; Peter Schuck; Mini Varughese; Arun P Chopra; Varsha Mehra; Yogendra Singh; Lisa M McGinnis; Stephen H Leppla
Journal:  J Biol Chem       Date:  2003-05-27       Impact factor: 5.157

9.  Changing the receptor specificity of anthrax toxin.

Authors:  Adva Mechaly; Andrew J McCluskey; R John Collier
Journal:  mBio       Date:  2012-05-01       Impact factor: 7.867

Review 10.  Understanding the mode of action of diphtheria toxin: a perspective on progress during the 20th century.

Authors:  R J Collier
Journal:  Toxicon       Date:  2001-11       Impact factor: 3.035

View more
  14 in total

1.  Solid tumor therapy by selectively targeting stromal endothelial cells.

Authors:  Shihui Liu; Jie Liu; Qian Ma; Liu Cao; Rasem J Fattah; Zuxi Yu; Thomas H Bugge; Toren Finkel; Stephen H Leppla
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-29       Impact factor: 11.205

Review 2.  Methods for the directed evolution of proteins.

Authors:  Michael S Packer; David R Liu
Journal:  Nat Rev Genet       Date:  2015-06-09       Impact factor: 53.242

Review 3.  Prodrug applications for targeted cancer therapy.

Authors:  Irene Giang; Erin L Boland; Gregory M K Poon
Journal:  AAPS J       Date:  2014-07-09       Impact factor: 4.009

4.  Type VI secretion system sheaths as nanoparticles for antigen display.

Authors:  Elena Del Tordello; Olga Danilchanka; Andrew J McCluskey; John J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-29       Impact factor: 11.205

5.  Identification of a Botulinum Neurotoxin-like Toxin in a Commensal Strain of Enterococcus faecium.

Authors:  Sicai Zhang; Francois Lebreton; Michael J Mansfield; Shin-Ichiro Miyashita; Jie Zhang; Julia A Schwartzman; Liang Tao; Geoffrey Masuyer; Markel Martínez-Carranza; Pål Stenmark; Michael S Gilmore; Andrew C Doxey; Min Dong
Journal:  Cell Host Microbe       Date:  2018-01-27       Impact factor: 21.023

Review 6.  Recent progress in enzymatic protein labelling techniques and their applications.

Authors:  Yi Zhang; Keun-Young Park; Kiall F Suazo; Mark D Distefano
Journal:  Chem Soc Rev       Date:  2018-09-27       Impact factor: 54.564

Review 7.  Channel-forming bacterial toxins in biosensing and macromolecule delivery.

Authors:  Philip A Gurnev; Ekaterina M Nestorovich
Journal:  Toxins (Basel)       Date:  2014-08-21       Impact factor: 4.546

8.  The activity of myeloid cell-specific VHH immunotoxins is target-, epitope-, subset- and organ dependent.

Authors:  Christopher Bachran; Matthias Schröder; Lena Conrad; Juan J Cragnolini; Fikadu G Tafesse; Laura Helming; Hidde L Ploegh; Lee Kim Swee
Journal:  Sci Rep       Date:  2017-12-20       Impact factor: 4.996

9.  An anthrax toxin variant with an improved activity in tumor targeting.

Authors:  Alexander N Wein; Diane E Peters; Zaheer Valivullah; Benjamin J Hoover; Aparna Tatineni; Qian Ma; Rasem Fattah; Thomas H Bugge; Stephen H Leppla; Shihui Liu
Journal:  Sci Rep       Date:  2015-11-20       Impact factor: 4.379

Review 10.  Tumor Targeting and Drug Delivery by Anthrax Toxin.

Authors:  Christopher Bachran; Stephen H Leppla
Journal:  Toxins (Basel)       Date:  2016-07-01       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.